An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

OBJECTIVE: Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII; VONCENTO(®), CSL Behring) is a high-concentration, low-volume, high-purity concentrate, which contains a high level of high-molecular-weight multimers and a VWF/FVIII ratio of ~2.4:1. The SWIFT (“Studies with von Willebrand fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lissitchkov, Toshko, Klukowska, Anna, Buevich, Evgeny, Maltceva, Irina, Auerswald, Guenter, Stasyshyn, Oleksandra, Seifert, Wilfried, Rogosch, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553254/
https://www.ncbi.nlm.nih.gov/pubmed/33117020
http://dx.doi.org/10.2147/JBM.S268907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553254/
https://www.ncbi.nlm.nih.gov/pubmed/33117020
http://dx.doi.org/10.2147/JBM.S268907

Ejemplares similares